Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKazankov, Konstantin-
dc.contributor.authorRode, Anthony-
dc.contributor.authorSimonsen, Kira-
dc.contributor.authorVilladsen, Gerda Elisabeth-
dc.contributor.authorNicoll, Amanda J-
dc.contributor.authorMøller, Holger Jon-
dc.contributor.authorLim, Lucy-
dc.contributor.authorAngus, Peter W-
dc.contributor.authorKronborg, Ian-
dc.contributor.authorArachchi, Niranjan-
dc.contributor.authorGorelik, Alexandra-
dc.contributor.authorLiew, Danny-
dc.contributor.authorVilstrup, Hendrik-
dc.contributor.authorFrystyk, Jan-
dc.contributor.authorGrønbæk, Henning-
dc.identifier.citationScandinavian Journal of Clinical and Laboratory Investigation 2016; 76(1): 64-73en_US
dc.description.abstractBACKGROUND: Tumor associated macrophages are present in hepatocellular carcinoma (HCC) and associated with a poor prognosis. The aim of the present study was to investigate the levels and dynamics of soluble (s)CD163, a specific macrophage activation marker, in patients with HCC. METHODS: In a cohort from Australia, we studied 109 HCC patients, 116 patients with chronic liver disease (CLD), and 52 healthy controls. We examined associations between baseline sCD163 and parameters of HCC severity as well as overall and progression-free survival. In a cohort of 42 Danish HCC patients, we measured sCD163 at baseline and 1, 4 and 12 weeks after ablative treatment. RESULTS: In the Australian cohort, median sCD163 was similarly increased in HCC (5.6[interquartile range 3.5-8.0] mg/L) and CLD (6.1[3.6-9.6] mg/L) patients as compared to controls (2.0[1.5-2.7] mg/L, p < 0.001). sCD163 correlated with Child-Pugh and MELD scores in both HCC and CLD patients. Patients with high sCD163 levels had shorter progression-free survival (p < 0.001), but not overall survival (p = 0.15). In the Danish cohort, patients with HCC progression at 12 weeks had an increase in sCD163. There was no association between sCD163 and HCC size, number, vascular invasion or metastasis in any of the cohorts. CONCLUSIONS: We confirmed increased sCD163 levels in CLD and HCC patients associated with Child-Pugh and MELD scores and portal hypertension, but not with HCC size and number, or metastasis. As a novel finding, baseline sCD163 appeared to predict a rapid HCC progression, as sCD163 increased during follow-up in HCC patients who showed progression.en_US
dc.subjectLiver diseaseen_US
dc.subjectTumor associated macrophagesen_US
dc.titleMacrophage activation marker soluble CD163 may predict disease progression in hepatocellular carcinomaen_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleScandinavian Journal of Clinical and Laboratory Investigationen_US
dc.identifier.affiliationDepartment of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmarken_US
dc.identifier.affiliationDepartment of Gastroenterology and Hepatology, Royal Melbourne Hospital, Melbourne, Australiaen_US
dc.identifier.affiliationDepartment of Gastroenterology, Eastern Health, Melbourne, Australiaen_US
dc.identifier.affiliationDepartment of Clinical Biochemistry, Aarhus University Hospital, Aarhus, Denmarken_US
dc.identifier.affiliationGastroenterology and Hepatologyen_US
dc.identifier.affiliationDepartment of Gastroenterology, Western Hospital, Melbourne, Australiaen_US
dc.identifier.affiliationEpicentre, Royal Melbourne Hospital, Melbourne, Australiaen_US
dc.identifier.affiliationMedical Research Laboratory, Department of Clinical Medicine, Health, Aarhus University, Aarhus, Denmarken_US
dc.identifier.affiliationVictorian Liver Transplant Uniten_US
dc.type.austinJournal Articleen_US, Peter W
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.grantfulltextnone- and Hepatology- Liver Transplant Unit- and Hepatology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

checked on Apr 16, 2024

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.